T790M

From WikiMD's WELLNESSPEDIA

T790M is a mutation in the EGFR gene, often associated with resistance to certain cancer treatments. This mutation is most commonly found in non-small cell lung cancer (NSCLC), and is a point mutation in the DNA sequence of the EGFR gene.

Overview[edit]

The T790M mutation is a specific change in the DNA sequence of the EGFR gene, where a threonine (T) is replaced by a methionine (M) at position 790. This mutation is often associated with resistance to tyrosine kinase inhibitors (TKIs), a type of cancer treatment. The T790M mutation is most commonly found in non-small cell lung cancer (NSCLC), but can also occur in other types of cancer.

Role in Cancer[edit]

The EGFR gene is involved in regulating cell growth and division. Mutations in this gene, such as the T790M mutation, can lead to uncontrolled cell growth and the development of cancer. The T790M mutation is often associated with resistance to tyrosine kinase inhibitors (TKIs), a type of cancer treatment. This resistance occurs because the mutation changes the shape of the EGFR protein, preventing the TKIs from effectively binding to it and blocking its activity.

Detection and Treatment[edit]

The T790M mutation can be detected using a variety of methods, including DNA sequencing and polymerase chain reaction (PCR). Treatment for cancers with the T790M mutation often involves the use of third-generation tyrosine kinase inhibitors (TKIs), which are designed to overcome the resistance caused by the mutation.

See Also[edit]



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.